Sex (N=849) Male 442 (52%)
Female 407 (48%)
Sex-ratio (male/female) 1,1
Age group (N=854) [0-1] 149 (17%)
[1-5] 257 (30%)
[5-10] 352 (41%)
[10-14] 96 (11%)
Average time of monitoring 20 ± 30 month  
Circonstances of screening (N=321) PMTCT 112 (35%)
Clinical suspicion 175 (55%)
Volontary test* 34 (11%)
Type of HIV (N=623) HIV1 621(99.7%)
HIV2 0 (0%)
HIV1+2 2 (0.3%)
WHO clinical stages (N=517) Stage 1 149 (29%)
Stage 2 112 (22%)
Stage 3 184 (36%)
Stage 4 72 (14%)
T4 lymphocytes number (N=624) Average for children 0-5 years 635±528
Average for children over 5 years 312±275
Therapeutic regimens (N=854) D4T 3TC NVP 528(61.8%)
AZT 3TC NVP 251(29.4%)
AZT 3TC EFV 25 (2.9%)
AZT 3TC ABC 2 (0.2%)
ABC DDI LPV/r 21 (2.5%)
ABC 3TC LPV/r 1 (0.1%)
AZT 3TC LPV/r 22 (2.6%)
TDF 3TC LPV/r 4 (0.5%)
Repartition of children in cohorts 2007 cohort 103(12.1%)
2008 cohort 68 (8%)
2009 cohort 219(25.6%)
2010 cohort 293(34.3%)
Unknown HAART initiation date 171 (20%)
N : number of disponible data; PMTCT : mother-to-child HIV transmission; D4T : stavudine; 3TC : lamivudine; NVP : nevirapine; ABC : abacavir; AZT : zidovudine; DDI : didanosine; TDF : tenofovir; EFV : efavirenz; LPV/r : lopinavir/ritonavir; * Testing on request of parents or gardians
Table 2: Characteristics of children included.